FAST‐CRISPR: Fusogenic Association and Secured Transfection of CRISPR/Cas9 Ribonucleoproteins Using Lipid‐Silica Hybrid Nanoparticles for Therapeutic Genome Editing

Why It Matters

FAST‑CRISPR overcomes the safety and efficiency limits of viral and conventional nanoparticle carriers, accelerating the path toward clinical genome‑editing therapies. Its endocytosis‑independent delivery cuts inflammatory risk while preserving editing potency.

Key Takeaways

• Lipid‑silica hybrids fuse directly with plasma membrane
• 1:1 DOTAP/DODMA lipids maximize RNP loading and release
• Large‑pore silica (≈20 nm) accommodates Cas9‑gRNA complexes
• In vivo, FAST‑CRISPR suppresses tumors without toxicity
• Bypasses endosomal escape, reducing inflammation risk

Pulse Analysis

The promise of CRISPR‑based therapeutics has been hampered by delivery bottlenecks, especially the immunogenicity and insertional risks of viral vectors. Conventional non‑viral carriers, such as lipid nanoparticles and polymeric complexes, rely on endocytosis and often suffer from inefficient endosomal escape, leading to payload degradation and inflammatory responses. These challenges have spurred intensive research into alternative platforms that can introduce ribonucleoprotein (RNP) complexes directly into the cytosol while maintaining biocompatibility.

FAST‑CRISPR addresses these hurdles through a hybrid architecture that merges porous silica nanoparticles with a finely tuned fusogenic lipid coat. The silica core, engineered with ~20 nm pores, securely houses Cas9‑gRNA RNPs, while the lipid shell—balanced between cationic DOTAP and ionizable DODMA—promotes spontaneous membrane fusion. This design bypasses the endocytic route entirely, delivering the editing machinery straight to the cytosol and facilitating swift nuclear translocation. Compared with traditional lipid‑nanoparticle formulations, the platform demonstrates superior loading capacity, rapid dispersion, and minimal off‑target immune activation.

Preclinical validation in a mouse xenograft model showed that multiplexed FAST‑CRISPR RNPs induce precise double‑strand breaks, trigger apoptosis in cancer cells, and achieve significant tumor regression without detectable systemic toxicity. The absence of endosomal disruption curtails inflammasome activation, positioning the technology as a safer, more efficient conduit for genome editing. As the field moves toward clinical trials, FAST‑CRISPR’s scalable, non‑viral nature could accelerate the deployment of precision medicines across oncology, genetic disorders, and beyond, reshaping the therapeutic landscape for gene‑editing applications.